- Beijing, December 14, China economic network the 117th review meeting of the municipal Party Committee on the science and technology innovation board in 2020 was held on December 11.
- The main business of Shengnuo Biotechnology is independent research and development, production and sales of peptide raw materials and preparation products.
- The total amount of shares to be issued by Shengnuo Biotechnology on the sci tech Innovation Board of Shanghai Stock Exchange shall not exceed 20 million shares, accounting for no less than 25% of the total share capital of the company after the issuance.
- The company has selected polypeptide generic drugs with large market capacity and strong market competitiveness at home and abroad for research and development.
Beijing, December 14, China economic network the 117th review meeting of the municipal Party Committee on the science and technology innovation board in 2020 was held on December 11.
The review results show that Chengdu Shengnuo Biotechnology Co., Ltd. (hereinafter referred to as “Shengnuo Biotechnology”) meets the issuance conditions, listing conditions and information disclosure requirements. This is the 197th science and technology innovation board enterprise to attend this year’s meeting.
The sponsor of this issuance of Shengnuo Biotechnology is Minsheng Securities Co., Ltd., and the sponsor representatives are Zhu Binghui and Bai Yingcai.
This is the 10th single technology innovation board project successfully recommended by Minsheng securities this year.
Prior to that, on April 27, Shanda Diwei Software Co., Ltd., which was sponsored by Minsheng securities, was first approved; on June 3, Guangzhou anbiping Pharmaceutical Technology Co., Ltd., which was sponsored by Minsheng securities, was first approved; on June 15, Zhejiang Ruisheng Intelligent Technology Co., Ltd., which was sponsored by Minsheng securities, was first approved;
on June 29, Zhejiang Heidemann intelligent equipment stock sponsored by Minsheng securities was approved On August 20, Zhuzhou oukeyi CNC Precision Cutting Tool Co., Ltd. was approved; on September 10, mingguan new materials Co., Ltd.
sponsored by Minsheng securities was approved; on October 27, Zhiyang Innovation Technology Co., Ltd. sponsored by Minsheng securities was held; on November 3, Hangzhou anxiu biological Co., Ltd. sponsored by Minsheng securities was held Science and Technology Co., Ltd.
and Guangdong Jiulian Technology Co., Ltd. In addition, on August 28, the review of Shenzhen Hanhong Digital Printing Group Co., Ltd. sponsored by Minsheng securities will be suspended; on November 9, the review of Shanghai Haoyuan Pharmaceutical Co., Ltd., which is sponsored by Minsheng securities, will be suspended.
The main business of Shengnuo Biotechnology is independent research and development, production and sales of peptide raw materials and preparation products.
Meanwhile, the company provides pharmaceutical research services for peptide innovative drugs, customized production services for peptide products and technology transfer services for domestic and foreign pharmaceutical enterprises.
In addition, the company also provides small molecule chemical drug levosimendan preparation processing and levosimendan API production, export sales business.
As of the date of signing the prospectus, Shengnuo Biotechnology directly holds 50.00% of the company’s shares and is the controlling shareholder of the company.
The actual controllers of the company are Wen Yongjun and Ma lanwen. Wen Yongjun directly holds 0.29% of the company’s shares, Ma lanwen directly holds 0.25% of the company’s shares, and Wen Yongjun indirectly holds 1.06% of the company’s shares through suno management.
Wen Yongjun and Ma lanwen indirectly hold 50.00% of the company’s shares through SINOSURE investment. The total direct and indirect shareholding ratio is 51.60%.
The total amount of shares to be issued by Shengnuo Biotechnology on the sci tech Innovation Board of Shanghai Stock Exchange shall not exceed 20 million shares, accounting for no less than 25% of the total share capital of the company after the issuance.
The number of shares to be issued shall be subject to the number registered by the CSRC. Shengnuo Biotechnology plans to raise 349 million yuan, of which 186 million yuan is used for the 395 kg / a peptide API production line project, 104 million yuan is used for the preparation industrialization technology transformation project, and 58.3318 million yuan is used for the upgrading project of Engineering Technology Center.
The main business of Shengnuo Biotechnology is independent research and development, production and sales of polypeptide raw materials and preparation products with large market capacity and strong competitiveness at home and abroad.
Meanwhile, relying on the technical advantages in the field of peptide drug research and development and large-scale production, the company provides peptide innovative pharmaceutical pharmaceutical research services, peptide product customization production services and peptide drugs for domestic and foreign pharmaceutical enterprises Product technology transfer services.
In addition, Shengnuo Biotechnology also provides small molecule chemical drug levosimendan preparation processing and levosimendan API production, export and sales business.
The company has selected polypeptide generic drugs with large market capacity and strong market competitiveness at home and abroad for research and development.
It has mastered the large-scale production technology of 15 varieties of API. Among them, 7 varieties have obtained the production approval in China, 8 varieties have obtained the record of DMF in the United States (active state), and the extended development of 7 polypeptide preparation varieties has obtained 11 production approval documents in China.
According to the prospectus, from 2017 to 2019 and from January to June 2020, the operating revenue of Shengnuo Biotechnology was RMB 194 million, RMB 278 million, RMB 377 million and RMB 176 million, and the net profit in the same period was RMB 33.9004 million, RMB 29.8613 million, RMB 48.1317 million and RMB 31311 million.
During the reporting period, the company’s net profit as a whole presents certain volatility. In addition, at the end of each reporting period, the book balance of accounts receivable of Shengnuo Biotechnology was 56.8459 million yuan, 70.3329 million yuan, 87.7063 million yuan and 97.0853 million yuan respectively, accounting for 16.33%, 14.71%, 16.90% and 17.32% of the total assets. With the continuous growth of the company’s operating income, the absolute amount of accounts receivable may further increase in the future.
This time, Shengnuo Biotechnology plans to raise about 349 million yuan, which will be used for “395 kg / a peptide API production line project”, “pharmaceutical industrialization technology transformation project” and “Engineering Technology Center upgrading project”.